Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - SHTN1 FGFR2 L617M |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - SHTN1 FGFR2 L617M | cholangiocarcinoma | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Futibatinib (TAS-120) in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | AZD4547 + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with AZD4547, demonstrating synergistic effects (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | resistant | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | cholangiocarcinoma | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Truseltiq (infigratinib) in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | Erdafitinib + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Sapanisertib (MLN0128) therapy restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Balversa (erdafitinib), demonstrating synergistic effects (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | cholangiocarcinoma | resistant | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | Infigratinib + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, addition of Sapanisertib (MLN0128) restored the sensitivity of transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M to treatment with Truseltiq (infigratinib), demonstrating synergistic effects (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | cholangiocarcinoma | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cholangiocarcinoma cells expressing both FGFR2-SHTN1 and FGFR2 E565A were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | resistant | AZD4547 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with AZD4547 in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M were sensitive to treatment with Iclusig (ponatinib) in culture, demonstrating reduced cell viability (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Truseltiq (infigratinib) in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | cholangiocarcinoma | resistant | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M demonstrated resistance to treatment with Balversa (erdafitinib) in culture (PMID: 31911531). | 31911531 | |
FGFR2 - SHTN1 FGFR2 L617M | Advanced Solid Tumor | sensitive | Ponatinib + Sapanisertib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination therapy of Iclusig (ponatinib) and Sapanisertib (MLN0128) resulted in synergistic effects in transformed cells expressing both FGFR2-SHTN1 and FGFR2 L617M in culture (PMID: 31911531). | 31911531 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|